Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;11(6):519-32.
doi: 10.1007/s11892-011-0234-7.

Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment

Siri Atma W Greeley  1 , Rochelle N Naylor, Louis H Philipson, Graeme I Bell
Affiliations
Review

Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment

Siri Atma W Greeley et al. Curr Diab Rep. 2011 Dec.

Abstract

There has been major progress in recent years uncovering the genetic causes of diabetes presenting in the first year of life. Twenty genes have been identified to date. The most common causes accounting for the majority of cases are mutations in the genes encoding the two subunits of the ATP-sensitive potassium channel (K(ATP)), KCNJ11 and ABCC8, and the insulin gene (INS), as well as abnormalities in chromosome 6q24. Patients with activating mutations in KCNJ11 and ABCC8 can be treated with oral sulfonylureas in lieu of insulin injections. This compelling example of personalized genetic medicine leading to improved glucose regulation and quality of life may-with continued research-be repeated for other forms of neonatal diabetes in the future.

PubMed Disclaimer

References

    1. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med. 2004;350(18):1838–1849. - PubMed
    1. Pearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med. 2006;355(5):467–477. - PubMed
    1. Støy J, Greeley SAW, Paz VP, et al. Diagnosis and treatment of neonatal diabetes: a United States experience. Pediatr Diabetes. 2008;9(5):450–459. - PMC - PubMed
    1. Iafusco D, Bizzarri C, Cadario F, et al. No beta cell desensitisa-tion after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes. Diabetologia. 2011 Aug 7; PMID: 21822789; - PubMed
    1. Rafiq M, Flanagan SE, Patch A-M, et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 2008;31(2):204–209. - PMC - PubMed

Publication types

MeSH terms